{"id":"W2149472508","doi":"10.1007/s10637-007-9090-3","title":"A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumors","year":2007,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":118,"is_retracted":false,"has_abstract":false,"ca_institutions":"Pyrogenesis (Canada)","funders":"","keywords":"Pharmacokinetics; Cmax; Medicine; Tolerability; Bioavailability; Nausea; Adverse effect; Pharmacology; Pharmacodynamics; Maximum tolerated dose; Cyclin-dependent kinase; Dysgeusia; Toxicity; Refractory (planetary science); Oral administration; Internal medicine; Cancer; Cell cycle","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001635189,0.002271293,0.002580162,0.0007906793,0.000595008,0.0009543988,0.001191539,0.001601028,0.004248644],"category_scores_gemma":[0.001033831,0.0009039931,0.001570868,0.0005615705,0.001557796,0.001036535,0.0003393466,0.004431476,0.00105777],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001084324,"about_ca_system_score_gemma":0.002696188,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002411867,"about_ca_topic_score_gemma":0.007041622,"domain_scores_codex":[0.9995448,0.0002233243,0.00001280033,0.00007223982,0.00004037204,0.0001064363],"domain_scores_gemma":[0.9992385,0.0001587834,0.00008857439,0.00006029831,0.00003858378,0.0004152101],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6619341,0.1365551,0.005351201,0.000903803,0.001448444,0.0005040853,0.0005770196,0.005920904,0.07856636,0.0009788224,0.01097191,0.09628828],"study_design_scores_gemma":[0.5571852,0.4229033,0.00623882,0.00002724442,0.0004611403,0.000422429,0.00009726492,0.001906259,0.006479457,0.0003606356,0.003878377,0.00003989723],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9879522,0.001995121,0.0009989797,0.0009566107,0.000273222,0.002550493,0.001891814,0.0001507936,0.003230859],"genre_scores_gemma":[0.9752666,0.003319918,0.003351347,0.001611239,0.0003944143,0.003983098,0.005334057,0.0001027092,0.00663673],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004248644,"threshold_uncertainty_score":0.01421314,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02381757120153434,"score_gpt":0.3125895757310258,"score_spread":0.2887720045294915,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}